engleski

Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats

Aim: Rectovaginal fistula is a devastating condition providing more than 99% of patients for surgical treatment. We hypothesized that rectovaginal fistula may be healed by therapy with stable gastric pentadecapeptide BPC 157, in consistence with its initial clinical application and effect on external fistulas. Main methods: BPC 157 (10 µg/kg or 10 ng/kg) was given perorally, in drinking water (0.16 µg/ml or 0.16 ng/ml, 12 ml/rat/day) till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24h before sacrifice. Controls simultaneously received an equivolume of saline (5.0 ml/kg ip) or water only (12 ml/rat/day). The assessment (i.e., rectal and vaginal defect, fistula leakage, defecation through the fistula, adhesions and intestinal obstruction as healing processes) was at day 1, 3, 5, 7, 10, 14 and 21. Key findings: Regularly, rectovaginal fistulas exhibited poor healing, with both of the defects persisting, continuous fistula leakage, defecation through the fistula, advanced adhesion formation and intestinal obstruction. By contrast, BPC 157 given perorally or intraperitoneally, in µg- and ng-regimens rapidly improved the whole presentation, with both rectal and vaginal defects simultaneously ameliorated and eventually healed. The maximal instilled volume was continuously raised till the values of healhty rats were achieved, there were no signs of defecation through the fistula. A counteraction of advanced adhesion formation and intestinal obstruction was achieved. Microscopic improvement was along with macroscopic findings. Significance: BPC 157 effects appear to be suited to induce a full healing of rectovaginal fistulas in rats.

BPC 157 ; rectovaginal fistula ; healing ; rats

Profesor Žarko Rašić je voditelj projekta 108-1083570-3636, budući da je profesor Tomislav Anić već nekoliko godina u mirovini.